In 2016, German pharma giant Bayer took a bold step and decided to partner with CRISPR Therapeutics to form a company that could join the race to be first into … Continue Reading The Race to Get CRISPR to the Clinic: Hope Versus Hype
The typical way for a biotech to launch is for a scientist, often academia-based, to have come up with a discovery that shows commercial promise—sometimes rather far down the line. … Continue Reading Crowdsource Funding to Launch a Biotech: Is it as Crazy as it Sounds?
Hemophilia B patients have some good news to cheer. Data suggests that uniQure’s AAV5 gene therapy may be viable treatments for 97 percent of patients. Over the weekend the company … Continue Reading uniQure, Bioverativ Unveil Positive Data for Hemophilia B and Hemophilia A Patients
For investors looking for a big pharma stock, AbbVie and Pfizer are both top choices. Over the last five years, AbbVie is up approximately 130 percent. That’s a clear winner over … Continue Reading Investors: Making the Case for Pfizer or AbbVie
San Diego-based Bloom Science launched to develop epilepsy treatments based on a new class of neuroprotective drugs. The company, whose research was published in the journal Cell today, focuses on … Continue Reading Bloom Science Launches from Exclusive UCLA Tech License
Genomic medicine is the future of healthcare. Spawned by the Human Genome Project (“HGP”), this precise and personal approach to medicine is an emerging discipline with enormous disruptive … Continue Reading Genomic Medicine: Catch The Gene Therapy Wave
One of the most promising and exciting healthcare innovations in decades is genomic editing technology using CRISPR technology to repair defective genetic material that causes disease. CRISPR is an … Continue Reading Is Genome Editing the Next Biotech Breakthrough?
On April 5, San Francisco’s Eidos Therapeutics closed on a Series B financing round worth $64 million. Now the company has filed with the U.S. Securities and Exchange Commission … Continue Reading Two Months After Raising $64 Million, Eidos Therapeutics Announces IPO
With the U.S. Food and Drug Administration (FDA) approvals of tisagenlecleucel (Kymriah)1 and axicabtagene ciloleucel (Yescarta),2 chimeric antigen receptor (CAR) T-cell therapy has moved into real-world practice, offering new potentially … Continue Reading Logistics of CAR T-Cell Therapy in Real-World Practice
Is your New Year’s resolution to read more? We here at STAT have you covered. This year saw the publication of some page-turning memoirs, deeply researched works of nonfiction, and … Continue Reading 10 great health and science books from 2017
J. Craig Venter shared on Twitter last week that he is retiring from Human Longevity, and returning to the J. Craig Venter Institute (JCVI) to continue his work. When Craig … Continue Reading Genomics Pioneer J. Craig Venter Retires from Human Longevity
Adoptive Cell Transfer Method Using RNAi Treatment Cancer immunotherapy has made significant strides in recent years, especially in the development of treatments for solid tumors. Of the several approaches to … Continue Reading Cancer Immunotherapy and RNA Interference Approach Seems to Present a Promising Matchup
Lesson 1: Definiteness of Purpose Definiteness of purpose is the starting point of all achievement. Without a purpose and a plan, people drift aimlessly through life. Related: Answer … Continue Reading Napoleon Hill’s 17 Principles of Personal Achievement
Σε επενδύσεις 55 εκατομμυρίων δολαρίων προχωρά η φαρμακευτική επιχείρηση Novartis για την ανέγερση νέας μονάδας παραγωγής στο Durham, της Βόρειας Καρολίνα. Για το νέο εργοστάσιο, στο οποίο η εταιρεία εκτιμά … Continue Reading Επενδύσεις 55 εκατ. για νέα μονάδα και προσλήψεις 200 ατόμων από την Novartis
Shares of CRISPR Therapeutics plunged dramatically Wednesday after the U.S. Food and Drug Administration (FDA) placed a clinical hold on a planned sickle cell disease treatment the company was in … Continue Reading FDA Chains Clinical Hold on CRISPR/ Vertex Sickle Cell Disease IND
Over the last five years, AbbVie shares are up about 130 percent. It’s generally viewed as a volatile stock—although to be fair, almost all biopharma stocks are—but some have argued … Continue Reading AbbVie Is a Great Short-Term Investment but Long-Term Is More Complicated